Drugs that contain Sildenafil Citrate
1. Liqrev patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11337979 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
| US11464778 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
| US11759468 | CMP DEV LLC | Liquid oral formulations for sildenafil |
Dec, 2038
(14 years from now) | |
Market Authorisation Date: 28 April, 2023
Treatment: Liqrev is indicated for the treatment of pulmonary arterial hypertension (who group 1) in adults to improve exercise ability and delay clinical worsening
Dosage: SUSPENSION;ORAL
More Information on Dosage
LIQREV family patents
2. Revatio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5250534 (Pediatric) | VIATRIS | Pyrazolopyrimidinone antianginal agents |
Sep, 2012
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-287) | Jan 31, 2026 |
| Orphan Drug Exclusivity(ODE-469) | Jan 31, 2030 |
| New Dosing Schedule(D-137) | Jan 31, 2017 |
| M(M-133) | Jan 31, 2017 |
| New Indication(I-598) | May 07, 2012 |
| M(M-61) | Aug 30, 2015 |
| Pediatric Exclusivity(PED) | Nov 07, 2012 |
Market Authorisation Date: 03 June, 2005
Treatment: NA
Dosage: TABLET;ORAL; SOLUTION;INTRAVENOUS
More Information on Dosage
REVATIO family patents
3. Viagra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5250534 (Pediatric) | VIATRIS | Pyrazolopyrimidinone antianginal agents |
Sep, 2012
(11 years ago) | |
| US6469012 | VIATRIS | Pyrazolopyrimidinones for the treatment of impotence |
Oct, 2019
(4 years ago) | |
|
US6469012 (Pediatric) | VIATRIS | Pyrazolopyrimidinones for the treatment of impotence |
Apr, 2020
(4 years ago) | |
Market Authorisation Date: 27 March, 1998
Treatment: Treatment of erectile dysfunction
Dosage: TABLET;ORAL
How can I launch a generic of VIAGRA before it's drug patent expiration?
More Information on Dosage
VIAGRA family patents